Reata Pharmaceuticals, Inc. - (RETA) Social Stream



Reata Pharmaceuticals, Inc. - (RETA): $43.39

2.53 (+6.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

REATA PHARMACEUTICALS INC (RETA) Price Targets From Analysts

Use the tables below to see what analysts covering REATA PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 8 $282 $155 $220.25 $41.61 429.32%
2021-12-07 7 $282 $112 $205.875 $41.61 394.77%
2021-12-09 8 $244 $35 $94.625 $41.61 127.41%
2022-03-01 8 $244 $35 $80.625 $41.61 93.76%
2022-03-02 8 $244 $35 $80.875 $41.61 94.36%
2022-05-04 6 $244 $35 $80.875 $41.61 94.36%
2022-05-11 7 $244 $35 $80.875 $41.61 94.36%
2022-05-24 7 $75 $35 $58.5 $41.61 40.59%
2022-08-09 8 $75 $35 $57.111 $41.61 37.25%
2022-08-11 8 $75 $27 $51 $41.61 22.57%
2022-10-11 8 $75 $27 $51.222 $41.61 23.1%
2022-10-19 9 $75 $27 $53.6 $41.61 28.82%
2022-11-08 10 $75 $27 $53.6 $41.61 28.82%
2022-11-09 10 $86 $27 $56.2 $41.61 35.06%
2022-11-28 10 $115 $27 $61.1 $41.61 46.84%

The Trend in the Analyst Price Target


Over the past 22 months, RETA's average price target has gone down $185.65.

RETA reports an average of 141.29% for its upside potential over the past 39 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-05-04 6 244 35 80.875 27.00 199.54%
2022-05-11 7 244 35 81.111 22.71 257.16%
2022-08-11 8 75 27 51.000 20.96 143.32%
2022-11-08 10 75 27 53.600 40.29 33.04%
2022-11-09 10 86 27 56.800 38.27 48.42%

RETA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.4 8 0 2 0 0 10

The Trend in the Broker Recommendations


RETA's average broker recommendation rating improved by 0.1 over the prior 35 weeks.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, REATA PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1888.06% of them.
  • RETA has a higher average analyst price target than 1807.07% of Pharmaceutical Products stocks.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, REATA PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 795.74% of them.
  • In terms of how REATA PHARMACEUTICALS INC fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is greater than 1479.5% of that group.

Stocks similar to REATA PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are AXSM, BPMC, and MCRB.

What is the outlook for RETA? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6453 seconds.